Mattheus K Reinders

Summary

Affiliation: Atrium Medical Centre
Country: The Netherlands

Publications

  1. ncbi Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
    M K Reinders
    Department of Clinical Pharmacy and Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
    Ann Rheum Dis 68:51-6. 2009
  2. ncbi A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
    M K Reinders
    Department of Pharmacy, University of Groningen, The Netherlands
    Ann Rheum Dis 68:892-7. 2009
  3. ncbi Management of hyperuricemia in gout: focus on febuxostat
    Mattheus K Reinders
    Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands
    Clin Interv Aging 5:7-18. 2010
  4. ncbi Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients
    Mattheus K Reinders
    Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands
    Clin Rheumatol 26:1459-65. 2007
  5. ncbi A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection
    Mattheus K Reinders
    Department of Clinical Pharmacy and Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
    J Pharm Biomed Anal 45:312-7. 2007
  6. ncbi New advances in the treatment of gout: review of pegloticase
    Mattheus K Reinders
    Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands
    Ther Clin Risk Manag 6:543-50. 2010

Collaborators

Detail Information

Publications6

  1. ncbi Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
    M K Reinders
    Department of Clinical Pharmacy and Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
    Ann Rheum Dis 68:51-6. 2009
    ..To investigate the efficacy and tolerability of allopurinol as the first-choice antihyperuricaemic treatment for gout, and compare the efficacy and tolerability of benzbromarone and probenecid as second-choice treatment...
  2. ncbi A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
    M K Reinders
    Department of Pharmacy, University of Groningen, The Netherlands
    Ann Rheum Dis 68:892-7. 2009
    ..To compare the efficacy and tolerability of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day used to attain a target serum urate concentration (sUr) < or =0.30 mmol/l (5 mg/dl)...
  3. ncbi Management of hyperuricemia in gout: focus on febuxostat
    Mattheus K Reinders
    Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands
    Clin Interv Aging 5:7-18. 2010
    ..Long-term safety data and efficacy data on tophus diminishment and reduction of gout flares have recently become available. Febuxostat may provide an important option in patients unable to use allopurinol, or refractory to allopurinol...
  4. ncbi Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients
    Mattheus K Reinders
    Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands
    Clin Rheumatol 26:1459-65. 2007
    ..In patients failing on allopurinol monotherapy, the addition of probenecid proves to be an effective treatment strategy for attaining sUr target levels (86% success)...
  5. ncbi A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection
    Mattheus K Reinders
    Department of Clinical Pharmacy and Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
    J Pharm Biomed Anal 45:312-7. 2007
    ....
  6. ncbi New advances in the treatment of gout: review of pegloticase
    Mattheus K Reinders
    Clinical Pharmacy, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands
    Ther Clin Risk Manag 6:543-50. 2010
    ..According to the current clinical data, pegloticase might have an important role as a (bridging) treatment in sUr-responsive patients for tophi clearance in severe chronic refractory gout...